This study aims to examine how effective a new vaccine is against a specific type of pneumonia. The vaccine is called the **20-valent pneumococcal conjugate vaccine (20vPnC)**. It targets a bacteria known as Streptococcus pneumoniae, which causes pneumonia. Participants should be aged 65 or older, be in the hospital due to suspected pneumonia, and have proof of pneumonia through a chest x-ray. During the study, participants will share their medical history and provide a urine sample to test for the pneumonia bacteria. The study lasts about 1-2 days, but information will be collected for up to 30 days through hospital records.
- Study lasts about 1-2 days, with follow-up for 30 days.
- Participants need to provide medical history and a urine sample.
- Participants must be aged 65+ and have pneumonia confirmed by a chest x-ray.
How understandable was the trial content above?
Hard to understand
Easy to understand